Phosphodiesterase type 5 inhibitors usage and prostate cancer

A match-paired analysis

G. Luke Machen, M. Hasan Rajab, Jessica Pruszynski, K. Scott Coffield

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: To treat erectile dysfunction (ED), phosphodiesterase type 5 inhibitors (PDE5i) are commonly used. However, to date, only a few studies exist evaluate a possible effect on the incidence of prostate cancer. One such study completed by the authors' institution suggested men who use PDE5i for ED may have a lower incidence of prostate cancer. This study was meant to address some of the shortcomings of the former study and further characterize the link between prostate cancer and PDE5i use. Methods: A retrospective, match-paired analysis was undertaken: 5,717 patients were identified between 2000 and 2011; a 1:2 match pair analysis ultimately identified 394 cases with cancer and 788 controls without cancer. Pairs were matched based on age, ethnicity, and PSA value. Results: No correlation existed between PDE5i use and prostate cancer [OR 1.02, 95% confidence interval (CI): 0.78-1.35, P=0.8842] or diabetes mellitus and prostate cancer (OR 1.12, 95% CI: 0.84-1.48, P=0.4499). A statistically significant correlation was demonstrated with PSA and prostate cancer (OR 1.48, 95% CI: 1.38-1.58, P < 0.0001). Conclusions: The data suggest that there is essentially no association with PDE5i use and prostate cancer.

Original languageEnglish (US)
Pages (from-to)879-882
Number of pages4
JournalTranslational Andrology and Urology
Volume6
Issue number5
DOIs
StatePublished - Oct 1 2017

Fingerprint

Phosphodiesterase 5 Inhibitors
Prostatic Neoplasms
Erectile Dysfunction
Confidence Intervals
Incidence
Neoplasms
Diabetes Mellitus

Keywords

  • Erectile dysfunction (ED)
  • Phosphodiesterase inhibitors
  • Prostate cancer
  • Prostate neoplasm

ASJC Scopus subject areas

  • Reproductive Medicine
  • Urology

Cite this

Phosphodiesterase type 5 inhibitors usage and prostate cancer : A match-paired analysis. / Machen, G. Luke; Rajab, M. Hasan; Pruszynski, Jessica; Coffield, K. Scott.

In: Translational Andrology and Urology, Vol. 6, No. 5, 01.10.2017, p. 879-882.

Research output: Contribution to journalArticle

Machen, G. Luke ; Rajab, M. Hasan ; Pruszynski, Jessica ; Coffield, K. Scott. / Phosphodiesterase type 5 inhibitors usage and prostate cancer : A match-paired analysis. In: Translational Andrology and Urology. 2017 ; Vol. 6, No. 5. pp. 879-882.
@article{00b3ffb82607488fa7b76c31349e21ff,
title = "Phosphodiesterase type 5 inhibitors usage and prostate cancer: A match-paired analysis",
abstract = "Background: To treat erectile dysfunction (ED), phosphodiesterase type 5 inhibitors (PDE5i) are commonly used. However, to date, only a few studies exist evaluate a possible effect on the incidence of prostate cancer. One such study completed by the authors' institution suggested men who use PDE5i for ED may have a lower incidence of prostate cancer. This study was meant to address some of the shortcomings of the former study and further characterize the link between prostate cancer and PDE5i use. Methods: A retrospective, match-paired analysis was undertaken: 5,717 patients were identified between 2000 and 2011; a 1:2 match pair analysis ultimately identified 394 cases with cancer and 788 controls without cancer. Pairs were matched based on age, ethnicity, and PSA value. Results: No correlation existed between PDE5i use and prostate cancer [OR 1.02, 95{\%} confidence interval (CI): 0.78-1.35, P=0.8842] or diabetes mellitus and prostate cancer (OR 1.12, 95{\%} CI: 0.84-1.48, P=0.4499). A statistically significant correlation was demonstrated with PSA and prostate cancer (OR 1.48, 95{\%} CI: 1.38-1.58, P < 0.0001). Conclusions: The data suggest that there is essentially no association with PDE5i use and prostate cancer.",
keywords = "Erectile dysfunction (ED), Phosphodiesterase inhibitors, Prostate cancer, Prostate neoplasm",
author = "Machen, {G. Luke} and Rajab, {M. Hasan} and Jessica Pruszynski and Coffield, {K. Scott}",
year = "2017",
month = "10",
day = "1",
doi = "10.21037/tau.2017.06.02",
language = "English (US)",
volume = "6",
pages = "879--882",
journal = "Translational Andrology and Urology",
issn = "2223-4683",
publisher = "AME Publishing Company",
number = "5",

}

TY - JOUR

T1 - Phosphodiesterase type 5 inhibitors usage and prostate cancer

T2 - A match-paired analysis

AU - Machen, G. Luke

AU - Rajab, M. Hasan

AU - Pruszynski, Jessica

AU - Coffield, K. Scott

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Background: To treat erectile dysfunction (ED), phosphodiesterase type 5 inhibitors (PDE5i) are commonly used. However, to date, only a few studies exist evaluate a possible effect on the incidence of prostate cancer. One such study completed by the authors' institution suggested men who use PDE5i for ED may have a lower incidence of prostate cancer. This study was meant to address some of the shortcomings of the former study and further characterize the link between prostate cancer and PDE5i use. Methods: A retrospective, match-paired analysis was undertaken: 5,717 patients were identified between 2000 and 2011; a 1:2 match pair analysis ultimately identified 394 cases with cancer and 788 controls without cancer. Pairs were matched based on age, ethnicity, and PSA value. Results: No correlation existed between PDE5i use and prostate cancer [OR 1.02, 95% confidence interval (CI): 0.78-1.35, P=0.8842] or diabetes mellitus and prostate cancer (OR 1.12, 95% CI: 0.84-1.48, P=0.4499). A statistically significant correlation was demonstrated with PSA and prostate cancer (OR 1.48, 95% CI: 1.38-1.58, P < 0.0001). Conclusions: The data suggest that there is essentially no association with PDE5i use and prostate cancer.

AB - Background: To treat erectile dysfunction (ED), phosphodiesterase type 5 inhibitors (PDE5i) are commonly used. However, to date, only a few studies exist evaluate a possible effect on the incidence of prostate cancer. One such study completed by the authors' institution suggested men who use PDE5i for ED may have a lower incidence of prostate cancer. This study was meant to address some of the shortcomings of the former study and further characterize the link between prostate cancer and PDE5i use. Methods: A retrospective, match-paired analysis was undertaken: 5,717 patients were identified between 2000 and 2011; a 1:2 match pair analysis ultimately identified 394 cases with cancer and 788 controls without cancer. Pairs were matched based on age, ethnicity, and PSA value. Results: No correlation existed between PDE5i use and prostate cancer [OR 1.02, 95% confidence interval (CI): 0.78-1.35, P=0.8842] or diabetes mellitus and prostate cancer (OR 1.12, 95% CI: 0.84-1.48, P=0.4499). A statistically significant correlation was demonstrated with PSA and prostate cancer (OR 1.48, 95% CI: 1.38-1.58, P < 0.0001). Conclusions: The data suggest that there is essentially no association with PDE5i use and prostate cancer.

KW - Erectile dysfunction (ED)

KW - Phosphodiesterase inhibitors

KW - Prostate cancer

KW - Prostate neoplasm

UR - http://www.scopus.com/inward/record.url?scp=85032278844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032278844&partnerID=8YFLogxK

U2 - 10.21037/tau.2017.06.02

DO - 10.21037/tau.2017.06.02

M3 - Article

VL - 6

SP - 879

EP - 882

JO - Translational Andrology and Urology

JF - Translational Andrology and Urology

SN - 2223-4683

IS - 5

ER -